FDA and Reagan-Udall Foundation Convene August 2026 Meeting to Advance Drug Repurposing Selection Criteria

Manufacturing capacity already validated under 21 CFR Part 211 and existing safety dossiers could become strategic assets as the Reagan-Udall Foundation for the FDA convenes a hybrid public meeting on August 5, 2026, to shape how repurposing candidates for approved drugs are selected and prioritized.

The meeting, running 10:30 a.m. to 5:00 p.m. ET, will be held in person at the Foundation's rooftop meeting space at 1333 New Hampshire Avenue NW, Washington, DC, and simultaneously via webcast. It follows a recent Request for Information and will open with a review of submitted comments before moving into structured discussion on candidate prioritization frameworks.

For regulatory affairs leads, the agenda covers ground that intersects directly with submission strategy. Discussion topics include factors for selecting repurposing candidates, unmet medical need, strength of evidence, disease burden, and public health impact, alongside scientific, regulatory, and policy barriers that currently impede promising opportunities from advancing. Federal agency representatives, clinicians, researchers, and patient organizations are all expected to participate, giving RA teams a rare consolidated view of where agency thinking is heading on new-indication submissions for already-approved compounds.

Plant heads and QA directors have a parallel read here. Repurposing submissions that reference an approved drug's established manufacturing process and validated safety profile can compress development timelines, but only if process validation documentation and change control records are current and defensible. Any gap in GMP compliance history becomes a liability when a repurposing dossier draws on that manufacturing record as evidence of process consistency.

Organizations wishing to present during the public comment session must register and indicate that intent by 11:59 p.m. ET on July 21, 2026. Comments may address successful prioritization models from prior repurposing efforts, candidate selection criteria, or identified barriers at the scientific, regulatory, or policy level.

The outcome of the August meeting is expected to inform how the FDA and its partners structure future repurposing prioritization programs, making the comment record a meaningful input into the regulatory framework that will govern new-indication submissions for approved drugs.

Source: FDA / Reagan-Udall Foundation for the FDA via FDA.gov What's New: Drugs RSS Feed, July 9, 2026. Meeting scheduled August 5, 2026, 10:30 a.m. – 5:00 p.m. ET; hybrid format, webcast and in-person.